Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

MediMass Kft.. (7/22/14). "Press Release: Life Sciences Innovator Waters Acquires the REIMS Technology from MediMass". Budapest.

Organisations Organisation Waters Corporation (NYSE: WAT)
  Group Waters (Group)
  Organisation 2 MediMass Kft.
  Today Waters Corporation (NYSE: WAT)
  Group Waters (Group)
Products Product Rapid Evaporative Ionization Mass Spectrometry technology (REIMS technology)
  Product 2 iKnife (Imperial College)
Index term Index term MediMass–Waters: investment, 201407 acquisition virtually all assets which comprise REIMS technology for iKnife by Waters
Persons Person Takáts, Zoltán (MediMass 2008– Founder + Professor at Imperial College London)
  Person 2 Tallos, Akos (MediMass 2008– Founder)

MediMass Ltd today announced that Massachusetts based Waters Corporation (WAT: NYSE) acquired its Rapid Evaporative Ionization Mass Spectrometry (REIMS) technology. The REIMS technology represents substantially all of the assets of MediMass and includes patent applications, software, databases and REIMS expertise.

REIMS is the enabling technology for the "Intelligent Knife" or "iKnife," a device in the conceptual stages of development that could in the future potentially be used for real-time diagnostics in surgery. Waters' experience with REIMS technology stems from a three-year collaboration among Waters, MediMass and Imperial College London focused on advancing REIMS. The goal of this relationship has been and continues to be advancing REIMS technology capabilities for health science applications.

REIMS is an ionization technique that can be used as a source for direct analysis of samples by mass spectrometry. To date, REIMS technology has shown the ability to bring ambient ionization sampling into real world applications such as food safety, microbiology and clinical diagnostic applications.

"While showing promise across many applications, REIMS technology significantly strengthens Waters' technology position within Health Sciences," said Rohit Khanna, Vice-President, Worldwide Marketing and Informatics, Waters Division. "We are delighted to join forces with Waters to continue the development of this potentially disruptive technology. The acquisition is proof of the ability of Hungarian science to develop world class innovations that may lead to improved patient care," said Akos Tallos MediMass Ltd.

About Medimass

The Company was launched in 2008 as a Semmelweis University related start-up to conduct research and development work based on the invention of scientist Dr. Zoltán Takáts. Akos Tallos together with 4 other individuals has been Mr Takats' committed partner in the venture right from the beginning.

It was Ildiko Polgar and her company ValDeal who first committed to support the research, seeing both the exceptional talent of the young team as well as the outstanding potential of the invention. Attila Várkonyi via his investment vehicle Fastventures Zrt joined the shareholder group at a critical moment when his financial commitment was key for the continuation of the business.

As a last financial investment round, Euroventures IV (JEREMIE co-investment fund) alongside its private co-investors Csaba Lantos and Miklos György agreed to join ValDeal and FastVentures in 2011 committing several rounds of equity financing in the range of €1-1.5m in order to take the project to the prototype phase when a strategic partner can be found to pursue with registration and respective commercial applications. The research leading to this success has also received funding from the European Union Seventh Framework Programme (FP7/2007-2013 under grant agreement n°305940. The Company has been controlled and managed by the Founding Partners all along, investors providing strategic support via an Advisory Committee.

About Waters Corporation (

For more than 50 years, Waters Corporation has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality, consumer products and high-value added chemicals worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.9 billion in 2013, Waters is driving scientific discovery and operational excellence for customers worldwide.

Waters is a registered trademarks of Waters Corporation

Record changed: 2016-03-19


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Waters (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75

» top